What is OncoMethylome Sciences?
OncoMethylome Sciences is a bio-tech firm dedicated to advancing cancer care through innovative diagnostic solutions. The company specializes in developing DNA gene methylation tests designed for the early detection of various cancers and for predicting patient responses to specific therapies or the likelihood of disease recurrence. These advanced diagnostic tools are intended to empower healthcare professionals and institutions by providing them with crucial information to enhance treatment efficacy and improve patient outcomes. The company's focus on precision medicine aims to redefine the standard of care in oncology.
How much funding has OncoMethylome Sciences raised?
OncoMethylome Sciences has raised a total of $21.9M across 2 funding rounds:
Share Placement
$12.1M
Grant
$9.7M
Share Placement (2007): $12.1M, investors not publicly disclosed
Grant (2009): $9.7M, investors not publicly disclosed
What's next for OncoMethylome Sciences?
With the recent major strategic investment, OncoMethylome Sciences is poised for accelerated growth and the expansion of its diagnostic offerings. The company is likely to focus on further research and development to refine its methylation test technology, potentially broadening its application to a wider range of cancers. Strategic partnerships with healthcare providers and pharmaceutical companies may also be a key focus to integrate their diagnostic solutions into clinical practice. This capital will also support efforts to scale operations, enhance market penetration, and navigate the complex regulatory pathways for diagnostic tests, solidifying its position as a leader in cancer diagnostics.
See full OncoMethylome Sciences company page
